Please assess the completion status of the following clinical trial:

Trial Title: A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with documented multiple myeloma (MM) satisfying the CRAB (calcium elevation, renal insufficiency, anemia, and bone abnormalities) criteria , monoclonal plasma cells in the bone marrow more than equal to (\>=) 10 percent (%) or presence of a biopsy proven plasmacytoma, and measurable disease Measurable disease as defined by any of the following: (a) immunoglobulin (Ig) G MM: serum monoclonal paraprotein (M protein) level \>=1.0 gram/deciliter (dL) or urine M protein level \>= 200 milligram(mg)/24 hours; or (b) IgA, IgM, IgD, or IgE MM: serum M protein level \>=0.5 g/dL or urine M protein level \>=200 mg/24 hours; or (c) Light chain MM without measurable disease in serum or urine: serum Ig free light chain (FLC) \>=10 mg/dL and abnormal serum Ig kappa lambda FLC ratio~* Participants newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to being \>=65 years old, or in subjects less than (\<) 65 years old presence of important comorbid condition(s) likely to have a negative effect on the tolerability of high-dose chemotherapy with ASCT~* Pretreatment clinical laboratory values meeting the following criteria during the Screening Phase~* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1~* A woman of childbearing potential must have 2 negative serum or urine pregnancy tests at Screening, first within 4 weeks prior to dosing and the second within 3 days prior to dosing~Exclusion Criteria:~* Participants with diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering MM~* Participant with plasma cell leukemia or other conditions in which Ig (immunoglobulin) M protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions~* Participants who have prior or current systemic therapy or ASCT for MM, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment~* Participants with history of malignancy (other than MM) within 5 years before the date of the first daratumumab administration~* Participants who have radiation therapy within 14 days of the first dose

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab with Lenalidomide and dexamethasone (Type: EXPERIMENTAL): Daratumumab (16 milligram per kilogram \[mg/kg\]) will be administered by intravenous \[IV\] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete